A method for preparing 2-mercaptobenzothiazole where the aniline method is adopted to perform reaction in the presence of a catalyst, and the catalyst includes sulfonic acid type imidazolium ionic liquid. The sulfonic acid type imidazolium ionic liquid is a type of acidic functionalized ionic liquid, and has the advantages of both a solid acid and a liquid acid. The sulfonic acid type imidazolium ionic liquid is adopted as an active ingredient of the catalyst, and may remarkably improve a conversion rate of the reaction raw materials and increase a yield of the 2-mercaptobenzothiazole. Meanwhile, due to the characteristics of high catalytic activity, no volatilization, low corrosion, high thermal stability and the like of the 2-mercaptobenzothiazole, the preparation method also has the comprehensive advantages of simple process, low cost, low tar yield, high environment friendliness and the like.

One example embodiment relates to a method of treating non-small cell lung cancer by administering a compound of formula (I) to a patient. Another example embodiment relates to a method of inhibiting progress of tumor growth in a patient with cancer, wherein tumor cells of the cancer have a mutant V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, and the method includes administering to the patient the compound with the following formula I: ##STR00001##

One example embodiment relates to a method of treating non-small cell lung cancer by administering a compound of formula (I) to a patient. Another example embodiment relates to a method of inhibiting progress of tumor growth in a patient with cancer, wherein tumor cells of the cancer have a mutant V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, and the method includes administering to the patient the compound with the following formula I: ##STR00001##

One embodiment relates to a method of treating lung cancer by administering a compound of formula I to a patient. Another embodiment relates to a method of treating cancer with a KRAS mutation that includes administering to a patient the compound with the following formula I: ##STR00001##

One embodiment relates to a method of treating lung cancer by administering a compound of formula I to a patient. Another embodiment relates to a method of treating cancer with a KRAS mutation that includes administering to a patient the compound with the following formula I: ##STR00001##

An electrical connection structure includes: a first metal member including copper or a copper alloy, a plated tin layer being formed on at least a portion of the first metal member; a second metal member that is electrically connected or connectable to the first metal member; and a surface treating layer formed on the surface of the first metal member. The surface treating layer is formed by applying a surface treating agent containing base oil and a metal affinity compound having a lipophilic group and an affinity group that has an affinity for metal. The metal affinity compound contains an adduct between an acidic alkyl phosphate ester and an azole compound and an adduct between an acidic alkyl phosphate ester and a metal and/or an organic amine compound.

An electrical connection structure includes: a first metal member including copper or a copper alloy, a plated tin layer being formed on at least a portion of the first metal member; a second metal member that is electrically connected or connectable to the first metal member; and a surface treating layer formed on the surface of the first metal member. The surface treating layer is formed by applying a surface treating agent containing base oil and a metal affinity compound having a lipophilic group and an affinity group that has an affinity for metal. The metal affinity compound contains an adduct between an acidic alkyl phosphate ester and an azole compound and an adduct between an acidic alkyl phosphate ester and a metal and/or an organic amine compound.